To our knowledge, the PPAR signalling pathway can function pleiotropically in cancer, and PPARα antagonists can be involved in the regulation of multiple reprogrammed metabolic pathways and attenuate tumor growth in renal cell carcinomas [48, 49]. This evidence concerns the gene PPARA and renal cell carcinoma.